#telehealth

2 stories

Regulatory April 7, 2026 · View digest

FDA Had Already Warned Telehealth Startup MEDVi Over Misbranded GLP-1 Drugs

MEDVi, a $1.8B AI-powered telehealth company with just two full-time employees, received an FDA warning letter in February 2026 for misbranding compounded semaglutide and tirzepatide.

Regulatory April 1, 2026 · View digest

FDA Warns 30 Telehealth Companies Over Compounded GLP-1 Marketing

The FDA issued warning letters to 30 telehealth firms for false or misleading claims about compounded GLP-1 weight-loss products, signaling a major crackdown on illegal online marketing.